Paediatrics II Flashcards
(186 cards)
Biochemical features of DKA
Hyperglycaemia (or history of diabetes)
Ketonaemia
Metabolic acidosis
Dehydration
Presentation of DKA
Polyuria
Polydipsia
Nausea + vomiting
Weight loss
Acetone smell to breath
Dehydration –> hypotension
Altered consciousness
Symptoms of underlying trigger e.g. sepsis
Diagnosis of DKA
Hyperglycaemia (>11mmol/L)
Ketosis (>3mmol/L, or >2+ on dipstick)
Acidosis (Venous pH <7.3, bicarbonate <15.0mmol/L)
Electrochemical imbalances in DKA
Mildly raised creatinine - sign of dehydration
Low bicarbonate - metabolic acidosis
Fluid management of DKA
0.9% NaCl (not dextrose) - give fluid bolus of 20ml/kg if in shock, 10ml/kg if not in shock
Given IV if N+V, or if clinically dehydrated
Correct dehydration over 48 hours
Further management of DKA
Give insulin after 1 hour of IV fluids: 0.1unit/kg/hour
Treat underlying triggers
Give IV dextrose once blood glucose <14mmol/L
Add potassium to IV fluids + monitor closely (40mmol/L)
How to calculate maintenance fluids in a child
First 10kg: 100ml/kg/day
10-20kg: 50ml/kg/day
>20kg: 20ml/kg/day
How to calculate fluid deficit in children
% dehydration x weight (kg) x 10
How to calculate hourly fluid requirements in children
= (fluid deficit-bolus given)/48 + maintenance hourly rate
NB: do not substract bolus given if given for shock
Fluid bolus use in children
20ml/kg of normal saline
In ?DKA, and HF, use 10ml/kg ue to fluid overload complications
Turner syndrome
Single X chromosome –> 45XO
Features of Turner syndrome
Short stature
Webbed neck
High arching palate
Downward sloping eyes with ptosis
Broad chest + widely spaced nipples
Cubital valgus
Multiple pigmented naevi
Underdeveloped ovaries with reduced function
Late or incomplete puberty
Most women are infertile
Conditions associated with Turner syndrome
Otitis media
UTIs
Coarctation of the aorta
Hypothyroidism
Hypertension
Obesity
Diabetes
Osteoporosis
LDs
Management of Turner syndrome
Growth hormone therapy - used to prevent short stature
Oestrogen + progesterone to help establish female secondary sex characteristics, regulate menstrual cycle and prevent osteoporosis
Fertility treatment
Definition of juvenile idiopathic arthritis
Group of chronic inflammatory arthritis diseases beginning before age of 16
Joint arthritis >6 weeks
Arthritis - swelling or effusion, increased warmth and/or painful limited movement +/- tenderness
Risk factors for JIA
Female
<6 years old
HLA polymorphisms
FHx autoimmunity
Presentation of JIA
Joint pain/swelling
May have fever - commonly observed in systemic-onset JIA
Morning stiffness
Limp
Limited movement
Rash - common in SoJIA, salmon-coloured on trunk + proximal ectremities. Or psoriatic rash if psoriatic arthritis
Enthesitis
Uveitis
Rheumatoid nodules
Imaging for JIA
Ultrasound - often abnormal early in disease. Can be used to identify joints for corticosteroid injection
MRI - may be required if monoarticular disease, useful to view synovial fluid
Phenotypic groups in JIA
Oligoarticular arthritis (arthritis of 4 or fewer joints)
Polyarticular arthritis (arthritis of 5 or more joints)
Active sacroilitis
Active enthesitis
Systemic-onset JIA
Management of polyarticular JIA
1st line = DMARD e.g. methotrexate (+ folic acid), or sulfasalazine
Consider biological therapy alongside DMARD e.g. TNF-alpha inhibitor (etanercept, adalimumab)
Consider NSAIDs
Consider intra-articular steroid injection (done under USS), or oral corticosteroids
Key information for oligoarticular JIA
4 joints or fewer
Most common form of JIA
Affects medium-sized joints e.g. knees + elbows
Most common in girls <6
Associated with anterior uveitis
Highest association with antinuclear antibody
Management of oligoarticular JIA
1st line = intra-articular corticosteroid
Consider: NSAIDs, methotrexate, TNF-alpha factor, oral corticosteroids
Management of active sacrolitis/active enthesitis JIA
1st line = NSAIDs
Consider: oral corticosteroids, sulfasalazine or TNF-alpha (methotrexate also in enthesitis)
Management of systemic-onset JIA
1st line: Oral or IV corticosteroid
Consider: NSAIDs, biological therapy e.g. tocilizumab